Zevra anticipates filing MIPLYFFA sNDA in Q1 2027 as CHMP opinion remains expected in Q4

• Progress with MIPLYFFA remained the core update, with CEO Neil McFarlane reporting, "total net revenue for the third quarter was $37.8 million" and "net U.S. product revenue for MIPLYFFA was $34 million," alongside launch tracking of "13 prescription enrollment

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.